

## SUBJECT INDEX

- Abdominal aortic aneurysm, preincisional transversus abdominis plane block, 536–538
- Accessory mitral valve, coarctation of aorta, without LVOTO, 549–550
- Acidosis, cardiotoxic effects, of colforsin and epinephrine, 925–931
- Activated coagulation time, 35
- Activated partial thromboplastin time, 30–33
- Activated protein C, 35–39
- Acute compartment syndrome, axillary cannulation, e63
- Acute kidney injury
- after aortic surgery, 1158–1165
  - during aortic arch reconstruction in infants, 1153–1157
  - Doppler-based renal resistive index, 890–895
  - oliguric criteria, after on-pump cardiac surgery, 1145–1152
  - reducing mortality, 1384–1398
- Adenosine diphosphate (ADP)-receptor inhibitors, perioperative management, 779–789
- Adhesive pericarditis, combined impairment of systolic and diastolic function, e82–e84
- Adult patients, transfusion changes undergoing liver transplantation, 41–44
- Air emboli, brain protection, cardiac surgery, 876–882
- Air embolization, extracorporeal membrane oxygenation, 341
- Airway intervention, aortic arch aneurysm, 796–801
- Airway management
- bronchial blocker, e61–e62
  - hemangioma of the tongue, 1337–1338
- Algorithm
- general anesthetic induction, 162–164
  - intraoperative anesthetic management, 64
  - for reverse cerebral desaturation, 1260–1266
- Aminocaproic acid, for blood conservation, 1201–1206
- Anatomic variation, artery exiting proximal aortic root, 410–412
- Anemia, clinical practice guideline implementation, 1189–1193
- Anesthesia. *See also* General anesthesia
- and hemodynamic management, left ventricular assist devices, 757
  - during hypothermic cardiopulmonary bypass, 59–61
  - isoflurane, effects on aortic compliance and systemic hemodynamics, 1282–1288
  - liver transplantation, 812–813
  - local epidural, fast-track abdominal aortic surgery, 451–457
  - thoracic epidural, mitral regurgitation, 445–450
  - total intravenous, fospropofol, CABG surgery, 908–914
  - transfemoral aortic valve replacement, 46–48
- Anesthesiologists, and echocardiographers/echocardiologists, 627
- Aneurysm
- aortic
    - abdominal, preincisional transversus abdominis plane block, 536–538
    - repair, HIV patients, 148  - aortic arch, airway intervention, 796–801
  - atrial septal, in cardiac surgery, 1339–1342
  - valsalva, noncoronary sinus of, 629–630
- Angiotensin II, 160–161, 164
- Angiotensin system inhibitor, cardiac surgery, 828–832
- Angiotensin-axis blockade, hypotension, 156–164
- Angiotensin-converting enzyme inhibitors, 156–164
- Anterior tracheal injury, during sternotomy, e60–e61
- Anticholinergic agents, 162
- Anticoagulants, extracorporeal membrane oxygenation, 30–33
- Anticoagulation, influence on antiplatelet P2Y<sub>12</sub> therapy, e69–e71
- Antifibrinolytics, S24
- Antiplatelet P<sub>2</sub>Y<sub>12</sub> therapy, influences of hemodilution and anticoagulation on, e69–e71
- Antithrombin, extracorporeal circulation, cardiac surgery, 230–236
- Aorta. coarctation of, in accessory mitral valve, 549–550
- Aortic abdominal aneurysmectomy, ischemia-reperfusion injury, 690–694
- Aortic arch aneurysm, airway intervention, 796–801
- Aortic arch reconstruction, acute kidney injury, 1153–1157
- Aortic disease, HIV, 143
- Aortic dissection
- acute ascending, Mustard procedure, 735–738
  - cesarean delivery and repair, 32 weeks of pregnancy, 731–733
  - type-A, pulmonary thromboembolism, right ventricular dilation, 1432–1434
- Aortic flow probe, thermodilution cardiac output measurement, 1133–1138
- Aortic root, proximal, artery exiting, 410–412
- Aortic stenosis, 190–192
- vortex formation time, aortic valve replacement, 660–663
- Aortic surgery
- acute kidney injury after, 1158–1165
  - intraoperative electrophysiological monitoring, 1364–1373
  - vocal cord paralysis, 522–526
- Aortic thrombus, proximal, 198
- Aortic valve
- implantation, endovascular transcatheter, 765–776
  - percutaneous closure, severe aortic insufficiency, left ventricular assist device, 1407–1413
  - prosthetic, three dimensional TEE, 1060–1063
  - three-dimensional echocardiography, 376–380
- Aortic valve bypass surgery, transesophageal echocardiography during, e22–e23
- Aortic valve replacement
- left ventricular outflow tract, 406–408
  - mortality
    - hemoglobin level, 716–721
    - patient-prosthesis mismatch, 647–652
    - vortex formation time, left ventricular systolic function, 660–663
- Apnea test, brain death, extracorporeal cardiopulmonary resuscitation, 312–314
- Appendage clot, left atrial, hemodynamic instability, 625–626
- Arginine vasopressin, 159, 163–164
- Arrhythmias
- left ventricular mass index, cardiac surgery, 292–296
  - postoperative, CABG surgery, e49–e50
- Arterial cannulation, 349–350, 353–354
- Arterial desaturation, tetralogy of Fallot repair, 631–633
- Arteriovenous extracorporeal membrane oxygenation, 329–342
- Artery, exiting proximal aortic root, 410–412
- Asymptomatic and symptomatic visual dysfunction, 884–888
- Atenolol vs. metoprolol, day-of-surgery heart rate, 298–303
- Atrial fibrillation
- of diabetes mellitus, e24–e25
  - pulmonary vein Doppler, 115
- Atrial septal aneurysm, in cardiac surgery, 1339–1342
- Atrial septal defect, percutaneous closure of, 400–402
- Atrium
- left, recurrent cardiac intimal sarcoma, 103–106
  - right, circular structure, 628–630
- Autonomic nervous system, in cardiac surgery patients, 485–492
- Axillary cannulation, acute compartment syndrome, e63
- Balloon-induced pulsatile perfusion, 238–243
- β-blockers, cardioprotection, remote ischemic preconditioning, 305–310
- Beta-blocking agents, on mortality, 834–843
- Biatrial mass, patent foramen ovale, 194–196
- Bibliometrics, geographic publication variations, 208–212
- Bilateral videothoroscopic sympathectomy, usage of EZ-blocker on, e71–e72
- Bioimpedance, thoracic, 126
- Bioreactance, 126–129
- Bispectral index monitoring, during anesthesia, for hypothermic cardiopulmonary bypass, 59–61
- Bivalirudin, extracorporeal membrane oxygenation, 30–33
- Bleeding complications, extracorporeal membrane oxygenation, 340
- Blood flow, left-heart bypass, pediatric patients, 542–545

- Blood loss  
 in thoracic aortic surgery, 1201–1206  
 topical and intravenous tranexamic acid after CABG surgery, 18–21
- Blood testing, plasma vs. whole, perioperative coagulopathy, S9–S13
- Blood transfusion  
 adult patients undergoing liver transplantation, 41–44  
 in hypothermic circulatory arrest with surgery, 1181–1187
- Body surface area, in morbidly obese patients, 1140–1144
- Boston Echo Course Physics and Hemodynamics Workshop, e53
- Brain death  
 apnea test, extracorporeal cardiopulmonary resuscitation, 312–314  
 therapeutic hypothermia, nonpulsatile continuous-flow mechanical circulatory devices, e8, e9–e10
- Brain emboli, distribution and differentiation, 865–873
- Brain ischemia, Narcotrend EEG device, e13–e14
- Bronchial blocker  
 airway management, e61–e62  
 tracheal repair, dilatational tracheostomy, 108–110
- Bronchial tear, in end-tidal carbon dioxide, thoracoscopic tracheoesophageal fistula repair, 539–541
- CABG surgery. *See* Coronary artery bypass graft (CABG) surgery
- Cangrelor  
 pharmacokinetics, 781  
 P2Y<sub>12</sub> platelet blocker, 621–622
- Cannulation, extracorporeal membrane oxygenation, 332–334
- Cardiac anesthesiologists, 87
- Cardiac anesthetic agents, 178–179, 180–182
- Cardiac arrest  
 during general anesthesia, 1334–1337  
 in transplanted hearts, 1374–1378
- Cardiac embolism, subclavian intraport catheter, e10–e11
- Cardiac index, in morbidly obese patients, 1140–1144
- Cardiac index measurements, after cardiac surgery, 1108–1112
- Cardiac output  
 carbon dioxide rebreathing, 122  
 echocardiography for estimation of, 1122–1126  
 estimated continuous cardiac output vs. thermodilution, 1128–1132  
 FloTrac/Vigileo monitor for, 1114–1120, 1122–1126  
 during infrarenal aortic cross-clamping, 1101–1106  
 in morbidly obese patients, 1140–1144  
 MostCare<sup>®</sup>/PRAM for estimation of, 1114–1120  
 thermodilution measurements vs. aortic flow probe, 1133–1138
- Cardiac preload, volume-responsiveness prediction, 1094–1099
- Cardiac risk stratification, 395–398
- Cardiac spindle cell sarcoma, left atrium, 103–106
- Cardiac surgery  
 air emboli, brain protection, 876–882  
 atrial septal aneurysm, impairment of venous drainage, 1339–1342  
 autonomic nervous system evaluation in, 485–492  
 $\beta$ -blockers, remote ischemic preconditioning, cardioprotection, 305–310  
 bronchial blocker vs. double-lumen tube, massive hemoptysis, e26–e28  
 cardiac index measurements after, 1108–1112  
 cerebral oximetry, 385–387  
 cervical and thoracic osteophytes, TEE, 319–320  
 Doppler-based renal resistive index, acute kidney injury, 890–895  
 extracorporeal circulation, antithrombin levels, 230–236  
 fibrinogen concentrate therapy, 12–16  
 fibrinogen supplementation, 1–3  
 FloTrac/Vigileo monitor for, 1114–1120, 1122–1126  
 fluid responsiveness after, 1087–1092  
 goal-directed coagulation management in perioperative period, 1347–1354  
 goal-directed therapy in, e1075–e1078  
 heparin reversal and removal, 853–857  
 heparin-induced hypotension, angiotensin system inhibitor, 828–832
- Cardiac surgery (*Continued*)  
 high thoracic epidural analgesia, 1301–1309, e32  
 iloprost, pulmonary hypertension/right ventricular dysfunction, 459–465  
 isolated high lactate or low central venous oxygen saturation, 1271–1276  
 left ventricular mass index, arrhythmias, 292–296  
 levosimendan for, 1224–1231  
 methylene blue as treatment for vasoplegia during, 1233–1237  
 milrinone on mortality, 220–227  
 minimally invasive, cardioplegia maldistribution, 614–618  
 morphine, postoperative hyperactive-type delirium, 933–937  
 myocardial protection, volatile anesthetics, 972–979  
 near-infrared spectroscopy  
   clinical utility, as standard monitor, 390–393  
   fluid challenges, 266–271  
 nefopam, early postoperative hyperalgesia, 427–434  
 neonatal, recombinant activated factor VIIa, e14–e15  
 neurocognitive outcomes, 958–968  
 noninvasive ventilation practice, e63–e64  
 outcomes and biochemical parameters following, 1174–1179  
 pediatric  
   laryngoscopic view, 516–520  
   ultrafiltration strategy, clinical outcomes, 897–902  
 propofol, neuron-specific enolase, 510–515  
 pulmonary hypertension, pathophysiology, perioperative management, and outcomes, 551–566  
 renin-angiotensin system inhibitors, preoperative effects, 703–708  
 reversal of decreases in cerebral saturation in high-risk, 1260–1266  
 right ventricular failure, 1212–1216  
   congenital heart disease, 723–726  
 septal myectomy, 383–384  
 steroids, dose and key trails, 1053–1058  
 systemic inflammatory response, inflammatory mediators, 983–1006  
 thoracic epidural analgesia  
   dismissal in, e32  
   outcome in low-to-moderate risk patients, 1301–1309  
   performance, e34–e35  
 thoracic epidural anesthesia, mitral regurgitation, 445–450  
 transesophageal echocardiography, episodic monoplane, 665–668  
 transfusion practices in, 1189–1193  
 volatile anesthetics, remote ischemic preconditioning, cardioprotection, 305–310
- Cardiac tamponade, thoracic-lumbar spinal decompression and fusion surgery, 98–99
- Cardiac transplantation  
 HIV patients, 148–149  
 unusual findings, 404–405
- Cardiomyopathy, HIV, 143
- Cardioplegia  
 maldistribution, minimally invasive cardiac surgery, 614–618  
 systemic inflammatory response, 993
- Cardiopulmonary bypass (CPB)  
 asymptomatic and symptomatic postoperative visual dysfunction, 884–888  
 balloon-induced pulsatile perfusion, diabetic patients, 238–243  
 bleeding and morbidity, plasma dilution, 845–850  
 blood product transfusion, 1174–1179  
 brain emboli, distribution and differentiation, 865–873  
 dexmedetomidine, cardioprotection, 710–715  
 double-lung transplantation, postoperative oxygenation, 467–472  
 fluid responsiveness after, 1087–1092  
 HIV+ patients, 149–150  
 hypertonic solution, extravascular lung water index, 273–281  
 hypothermic, in sevoflurane, 59–61  
 immobile transesophageal echocardiographic probe, 955–957  
 isoflurane, neurocognitive dysfunction, 502–507  
 left ventricular thrombus, heparin-induced thrombocytopenia, 744–747

- Cardiopulmonary bypass (CPB) (*Continued*)  
 levosimendan for, 1224–1231  
 methylene blue for treatment of vasoplegia during, 1233–1237  
 moyamoya, cerebral oxygen saturation monitoring, 740–742  
 oral triiodothyronine replacement therapy in, 1218–1223  
 postoperative bleeding, 1201–1206  
 pulmonary gas embolism, hypoxia, 951–953  
 right ventricular failure, 1212–1216  
 steroids in, 1053–1058  
 thrombin generation and protein C pathway, 35–39  
 transfusion plasma exchange, for altered heparin responsiveness, e58–e60  
 ulinastatin, type-A aortic dissection, deep hypothermic circulatory arrest, 479–483
- Cardiothoracic surgery, hemorrhage, S20–S30  
 Cardiothoracic and vascular critical care, 87  
 Cardiovascular cytotoxicity, HIV, 140  
 Cardiovascular disease, HIV+ patients, 139–140  
 Cardiovascular risk, liver transplantation, 812  
 Cardiovascular surgery, HIV patients, 147–149  
 Carotid endarterectomy  
 cognitive function and oxidative stress after, 1246–1251  
 electroencephalography vs. cerebral oximetry, ischemia detection, 1253–1258  
 general vs. regional anesthesia, 1379–1383
- Catecholamine, 161  
 Catheters, pulmonary artery, defects, e32–e34  
 Central venous cannulation, 351, 353  
 Central venous catheters  
 CABG surgery, 101–102  
 guidewire diagnosis, e25–e26  
 Centrifugation method, for blood separation, 1174–1179  
 Cerebral desaturation, high-risk cardiac surgery, 1260–1266  
 Cerebral malperfusion, carotid flow, type-A aortic dissection, 728–730  
 Cerebral oximetry  
 cardiac surgery, 385–387  
 vs. 12-lead electroencephalogram, ischemia detection, 1253–1258  
 Cerebral oxygen saturation  
 during carotid cross clamping, for carotid endarterectomy, 1253–1258  
 monitoring, moyamoya disease, 740–742  
 Cerebral oxygenation impairment, off-pump CABG surgery  
 revascularization, 245–250  
 Cervical fluorosis, e72–e73  
 Cervical osteophyte, in cardiac surgery, for TEE, 319–320  
 Clevidipine, von Hippel-Lindau disease, pheochromocytoma, 749–751  
 Clopidogrel, pharmacokinetics, 779–789  
 Coagulation factors, for blood conservation, 1181–1187  
 Coagulation management, goal-directed, cardiac surgery, 1347–1354  
 Coagulation markers, HIV+ patients, 145–146  
 Coagulopathy, perioperative, plasma vs. whole blood testing, S9–S13  
 Cognitive dysfunction, diabetic patients, impaired cerebrovascular carbon dioxide reactivity, 238–243  
 Cognitive performance, after carotid endarterectomy, 1246–1251  
 Colforsin, cardiotoxic effects of, on acidosis, 925–931  
 Computerized tomographic anatomic relationships, thoracic  
 paravertebral space, 1315–1320  
 Congenital heart disease, right ventricular failure, 723–726  
 Congestive heart failure, etomidate, 181  
 Continuous venovenous hemofiltration, 31–33  
 Conventional conductive cooling vs. conductive plus pericranial  
 convective cooling, 288–290  
 Coronary anomalies, left anterior descending artery, e44  
 Coronary artery  
 calcium scoring, 146  
 dissection, intraoperative epicardial sonography, 323–324  
 evaluation, HIV patients, 146  
 Coronary artery bypass graft (CABG) surgery  
 blood loss with combined topical and intravenous tranexamic acid, 18–21  
 cerebral oxygenation impairment, 245–250  
 Coronary artery bypass graft (CABG) surgery (*Continued*)  
 chest radiograph, unusual radio-opaque shadow, 634–635  
 dexmedetomidine, cardioprotection, 710–715  
 diabetic patients, postoperative cognitive dysfunction, 238–243  
 goal-directed therapy in, e1075–e1078  
 hemoglobin A<sub>1c</sub> levels before and after, 1167–1172  
 HIV patients, 147–148  
 on- and off-pump, cognitive outcomes, 253–264  
 on-pump vs. off-pump, 5–11  
 posterior glenohumeral joint dislocation, 101–102  
 postoperative cognitive dysfunction, pulmonary complications, 1267–1269  
 prasugrel, cardiac tamponade, e57–e58  
 reoperative, sternal-sparing approach, 315–317  
 robotic surgery, preferred technique, 802–804, e81  
 Coronary artery disease  
 HIV, 141–142  
 management of, 89  
 thiopental, 181  
 Coronary ostium  
 three dimensional TEE, transapical aortic valve implantation, e53–e54  
 transapical aortic valve implantation, 654–658  
 Coronary revascularization  
 extracorporeal circulation, minimal vs. conventional, 859–863  
 robotic surgery, 806–808, e81  
 CPB. *See* Cardiopulmonary bypass (CPB)
- Damage control resuscitation, S37  
 Desflurane-induced preconditioning, endothelial and inducible nitric  
 oxide synthase, 494–499  
 Dexamethasone, quality of recovery scores, e3–e4  
 Dexmedetomidine  
 based vs. propofol-based sedation, cardiac surgery, 1289–1294  
 CABG surgery, cardioprotection, 710–715  
 intravenous anesthetic agent, 147  
 Diabetic patients, impaired cerebrovascular carbon dioxide reactivity, 238–243  
 Dobutamine infusion effect, on sublingual microcirculation, 1239–1244  
 Doppler-based renal resistive index, acute kidney injury, 890–895  
 Double-lung transplantation, cardiopulmonary bypass, 467–472  
 Drug design therapy, challenges, e65, e66  
 Drug-drug interactions, HAART, 142  
 Dynamic preload indices, pulse contour analysis, 124–126  
 Dyssynchrony, mitral regurgitation, 1421–1424
- ε-aminocaproic acid, in children, tetralogy of Fallot surgery, 23–28  
 Early extubation, in sufentanil, after valve surgery, 63–69  
 Early postoperative hyperalgesia, nefopam, cardiac surgery, 427–434  
 Echocardiography, 129  
 for cardiac output estimation, 1122–1126  
 simulation training, 1034–1039  
 three-dimensional transesophageal, 190–192  
 Echodensity, right atrial, 1065–1066  
 Echogenic object, in left atrium, end-stage renal disease, 1429–1431  
 Editorials  
 Anesthesiologists and Transesophageal Echocardiography:  
 Echocardiographers or Echocardiologists?, 627  
 Aortic Stenosis and 3-Dimensional Echocardiography: The Saga  
 Continues, 192  
 Fibrinogen Supplementation in Cardiac Surgery: Where Are We  
 Now and Where Are We Going?, 1–3  
 Goal-Directed Therapy in Cardiac Surgery: Are We There Yet?,  
 1075–1078  
 Intrathecal Morphine: The Forgotten Child, 413–415  
 Mitral Regurgitation: Focusing on the Cause Rather than the  
 Effect, 1424  
 Mitral Valve Surgery in Octogenarians: Insights and Perspectives,  
 201–202  
 Percutaneous Closure of Atrial Septal Defects and 3-Dimensional  
 Echocardiography—Ingenuity and Improvisation, 402

- Editorials (*Continued*)  
 Right Heart Three Dimensional Echocardiography: Time for the Limelight?, 637–638  
 Three-Dimensional Echocardiography: Another Dimension of Imaging or Complexity?, 1064  
 Why We Should Continue to Publish Case Reports, 825–827
- Education  
 echocardiography skills, senior anesthesiology residents, 670–674  
 online simulation, TEE, 531–534
- Efficacy and safety studies  
 ε-aminocaproic acid in children, tetralogy of Fallot surgery, 23–28  
 fibrinogen concentrate, 2  
 total intravenous anesthesia, fospropofol, CABG surgery, 908–914
- Elinogrel  
 pharmacokinetics, 781  
 P2Y<sub>12</sub> platelet blocker, 622
- Emboli  
 air, brain protection, cardiac surgery, 876–882  
 brain, distribution and differentiation, 865–873
- Embolism  
 carbon dioxide, transesophageal echocardiography, e23–e24  
 pulmonary, patent foramen ovale, e30–e31
- Embolization of air, extracorporeal membrane oxygenation, 341
- End-stage renal disease, echogenic object in left atrium, 1429–1431
- Endarterectomy, carotid  
 anesthesia comparisons for, 1246–1251  
 cognitive function and oxidative stress after, 1246–1251  
 electroencephalography vs. cerebral oximetry, ischemia detection, 1253–1258
- Endothelial nitric oxide synthase, desflurane-induced preconditioning, 494–499
- Endothelial protein C receptor, 35, 38
- Endothelin-receptor antagonist, for right ventricular failure, 1212–1216
- Endovascular transcatheter aortic valve implantation, 765–776
- End-tidal carbon dioxide  
 thoracoscopic tracheoesophageal fistula repair, 539–541  
 and volumetric carbon dioxide, hemodynamically unstable patients, 681–683
- Ephedrine, 159, 163
- Epiaortic ultrasound, intraoperative iatrogenic type-A aortic dissection, 326–327
- Epinephrine, 164  
 cardiotoxic effects of, on acidosis, 925–931
- Eritoran, systemic inflammatory response, 1003
- Esmolol, venovenous extracorporeal membrane oxygenation, e40
- Esophageal Doppler technique, 122
- Estimated continuous cardiac output vs. thermodilution cardiac output, 1128–1132
- Etomidate, cardiac anesthetic agent, 178–179, 180–182
- Evidence-based perioperative practice, 87–88
- Extracorporeal cardiopulmonary resuscitation, brain death, apnea test, 312–314
- Extracorporeal circulation, minimal vs. conventional coronary revascularization, 859–863
- Extracorporeal membrane oxygenation, 30–33, 329–342  
 venovenous, esmolol, e40
- Extravascular lung water index, hypertonic solution, cardiac patients, 273–281
- EZ-blocker, usage on bilateral videothoroscopic sympathectomy, e71–e72
- Fast-track abdominal aortic surgery, local vs. epidural anesthesia, 451–457
- Femoral venous cannulation, 349
- Fibrinogen concentrate  
 efficacy and safety studies, 2  
 on-pump vs. off-pump coronary artery bypass graft surgery, 5–11  
 therapy, cardiac surgery, 12–16
- Fibrinogen supplementation, cardiac surgery, 1–3
- FloTrac®  
 flurbiprofen axetil, systemic vascular resistance index, 696–701  
 pulse contour analysis, 124–125
- Fluid responsiveness, during infrarenal aortic cross-clamping, 1101–1106
- Fluorosis, cervical, e72–e73
- Flurbiprofen axetil, FloTrac system, systemic vascular resistance index, 696–701
- Fospropofol, safety and efficacy studies, CABG surgery, 908–914
- Four-dimensional right ventricular volume assessment, 371–372
- Fractured venous catheter, e40–e41
- Fusion surgery, left ventricular wall rupture, 98–99
- Gastrointestinal bleeding, ventricular assist-device, hormonal therapy, 939–942
- General anesthesia. *See also* Anesthesia  
 cardiac arrest during, 1334–1337  
 hypotension, 156–164  
 vs. regional anesthesia for carotid endarterectomy, 1379–1383  
 transfemoral aortic valve replacement, 46–48
- Geographic publication variations, bibliometrics, 208–212
- Glucocorticoids, systemic inflammatory response, 997–998
- Glycogen synthase kinase-3β, phosphorylation, sevoflurane, 916–923
- Glycopyrrolate, 163
- Goal-directed coagulation  
 factor, plasma transfusion, S16–S18  
 management, in cardiac surgery, 1347–1354
- Goal-directed hemostatic therapy, POC testing, S24–S28
- Goal-directed therapy  
 in cardiac surgery, e1075–e1078  
 perioperative volume management, 1079–1085  
 transfusion, S6–S7
- Gut hypoxia. *See* Ischemia-reperfusion injury
- Heart  
 failure, levosimendan for treatment of, 1224–1231  
 foreign body removal, TEE guidance, 321–322  
 right  
 catheterization, 554–555  
 three dimensional TEE, 637–638  
 transplanted, cardiac arrest and neuromuscular blockade reversal agents, 1374–1378
- Heart-lung machine, 203–206
- Heart-lung transplantation, pulmonary hypertension, 565
- Hemangioma of the tongue, airway management and lung isolation, 1337–1338
- Hemodilution  
 influence on antiplatelet P<sub>2</sub>Y<sub>12</sub> therapy, e69–e71  
 systemic inflammatory response, 995
- Hemodynamic parameters  
 oral triiodothyronine therapy, 1218–1223  
 oxygen delivery optimization, e1075–e1078
- Hemodynamics  
 in morbidly obese patients, 1140–1144  
 pressure waveform analysis, 676–680  
 prostaglandin E<sub>1</sub> effects on, 1208–1211
- Hemoglobin A<sub>1c</sub>  
 prognostic biomarker, 760–763  
 renal complications and cut-off values of, 1167–1172
- Hemolysis, intravascular, 341
- Hemorrhage  
 cardiothoracic surgery, S20–S30  
 historic views, S3–S4  
 obligation to stop, S1–S2  
 obstetric, S44–S47  
 in trauma, S35–S40
- Hemostatic resuscitation, S46
- Heparin  
 extracorporeal membrane oxygenation, 30–33  
 reversal and removal, cardiac surgery, 853–857  
 unfractionated, 30

- Heparin-induced hypotension, cardiac surgery, 828–832
- Heparin-induced thrombocytopenia (HIT), 30–33, 341  
left ventricular thrombus, cardiopulmonary bypass, 744–747
- High thoracic epidural analgesia, cardiac surgery, 1301–1309, e32
- Highly active antiretroviral therapy (HAART), 135–150
- Hormonal therapy, gastrointestinal bleeding, ventricular assist-device, 939–942
- Human immunodeficiency virus-1 (HIV), cardiovascular operations, 135–150
- Hypercoagulability, S13
- Hypertension, pulmonary, pathophysiology, perioperative management, outcomes, in cardiac surgery, 551–566
- Hypotension  
angiotensin-axis blockade, 156–164  
permissive, S37–S38  
refractory postoperative, Alfieri repair of mitral valve, e21–e22
- Hypothermia, therapeutic  
on nonpulsatile continuous-flow after brain death, e8, e9–e10  
out-of-hospital ventricular fibrillation survivors, 288–290
- Hypothermic cardiopulmonary bypass, sevoflurane, 59–61
- Hypothermic circulatory arrest, proximal aortic surgery with, 1181–1187
- Hypoxia, pulmonary gas embolism, cardiopulmonary bypass, 951–953
- Iloprost, pulmonary hypertension/right ventricular dysfunction, cardiac surgery, 459–465
- Immune-mediated HIT, 341
- Immunomodulation, perioperative, HIV+ patients, 146–147
- Impaired cerebrovascular carbon dioxide reactivity, diabetic patients, 238–243
- In vitro whole blood perfusion model, antiplatelet P<sub>2</sub>Y<sub>12</sub> therapy, e69–e71
- Inducible nitric oxide synthase, desflurane-induced preconditioning, 494–499
- Inflammation markers, HIV+ patients, 145
- Inflammatory mediators, systemic inflammatory response, 983–1006
- Infrarenal aortic cross-clamping, fluid responsiveness, 1101–1106
- Inhalation agents, HIV patients, 147
- Intensive care unit  
chest CT scan, occult pulmonary embolism, 474–478  
transfusion clinical practice guideline implementation, 1189–1193
- Intensivist-directed team model, cardiac surgery, 1194–1199
- Internal jugular vein  
bullet embolization, e45–e46  
cannulation, 347–349  
clinical significance, cross-sectional area, 685–688
- International Consensus Group, decision-making, e28, e29–e30
- Intraoperative anesthetic management, algorithm for, 64
- Intraoperative electrophysiological monitoring, aortic surgery, 1364–1373
- Intraoperative epicardial sonography, coronary artery dissection, 323–324
- Intraoperative iatrogenic type-A aortic dissection, 326–327
- Intraoperative management  
extracorporeal membrane oxygenation, 337–340  
ischemic mitral regurgitation, 573–582  
left ventricular assist devices, noncardiac surgery, 755  
of pulmonary hypertension, 559–560
- Intraoperative transesophageal echocardiography  
pulmonary veins, 111–119  
right ventricular outflow tract sarcoma, e54–e55
- Intrathoracic catheter placement, ultrasound guided paravertebral block, e11–e12
- Intravascular hemolysis, 341
- Intravenous and topical tranexamic acid, CABG surgery, 18–21
- Intravenous anesthetic agents, HIV patients, 146–147
- Inverted T waves, electrocardiogram, 819–820
- Ischemia  
cerebral near-infrared regional spectroscopy vs. 12-lead electroencephalogram, 1253–1258
- Ischemia (*Continued*)  
spinal cord, on simvastatin, 79–83  
temporary focal cerebral, remote effect, acute kidney injury, 71–76
- Ischemia-reperfusion injury, aortic abdominal aneurysmectomy, 690–694
- Ischemic mitral regurgitation, intraoperative echocardiography, 573–582
- Isoflurane  
neurocognitive dysfunction, cardiopulmonary bypass, 502–507  
survival and myocardial infarction, 50–56
- Intrathecal morphine, 413–415
- Ketamine, cardiac anesthetic agent, 181
- Kidney injury, Doppler-based renal resistive index, 890–895
- Kolff, W.J., tribute to, 600–613
- Laryngoscopy, pediatric cardiac surgery, 516–520
- 12-Lead electroencephalogram, vs. near-infrared regional spectroscopy, ischemia detection, 1253–1258
- Left anterior descending artery, coronary anomalies, e44
- Left atrial anastomosis, 405
- Left atrial appendage clot, hemodynamic instability, 625–626
- Left atrial contrast opacification, tetralogy of Fallot repair, 631–633
- Left atrial mass, myxoma, 816–818
- Left atrial osteosarcoma, 817–818
- Left atrium  
echogenic object in, end-stage renal disease, 1429–1431  
recurrent cardiac intimal sarcoma, 103–106
- Left thoracotomy, reoperative CABG surgery, 315–317
- Left ventricular assist device  
patient autonomy, 1048–1050, 1051–1052  
perioperative closure of aortic valve, 1407–1413  
perioperative management, noncardiac surgery, 752–758
- Left ventricular diastolic dysfunction, pulmonary veins, 115–116
- Left ventricular mass index, arrhythmias, cardiac surgery, 292–296
- Left ventricular outflow tract, aortic valve replacement, 406–408
- Left ventricular outflow tract obstruction (LVOTO), 92–97  
accessory mitral valve, coarctation of aorta, 549–550
- Left ventricular systolic dysfunction, levosimendan for treatment of, 1224–1231
- Left ventricular systolic function, vortex formation time, aortic valve replacement, 660–663
- Left ventricular thrombus, cardiopulmonary bypass, heparin-induced thrombocytopenia, 744–747
- Left ventricular wall rupture, thoracolumbar spinal decompression and fusion surgery, 98–99
- Left-heart bypass, pediatric patients, blood flow, 542–545
- Left-sided pulmonary veins, 113
- Levosimendan  
effects on survival and adverse events after cardiac surgery, 1224–1231  
perioperative applications of, 361–365, e75–e77, e77–e78  
systemic inflammatory response, 1002  
vasoactive-inotropic score, e15–e16
- Lidocaine, administration, effects on propofol and tracheal intubation, 1295–1300
- Life support, peripheral venoarterial extracorporeal, e48–e49
- Lithium dilution, pulse contour analysis, 123
- Liver transplantation  
anesthesia care, 812–813  
cardiac surgery, 810–811  
cardiovascular risk after, 812  
metabolic management, 811–812  
postreperfusion syndrome, 809–810  
renal dysfunction, 811  
transfusion changes, 41–44  
vasoplegia, 810
- Local vs. epidural anesthesia, fast-track abdominal aortic surgery, 451–457
- Low-dose spinal morphine, post-thoracotomy pain, 417–422

- Low-frequency jet ventilation, percutaneous dilatational tracheostomy, 108–110
- Lung harvesting, surgical procedure, 468
- Lung isolation, hemangioma of the tongue, 1337–1338
- Lung resection, cardiac risk stratification, 397
- Lung transplantation
  - pulmonary hypertension, 565
  - and pulmonary veins, 117
- Lung-liver transplantation, combined bilateral, 1343–1346
- Medical consultation, risk stratification, 396
- Mesenteric traction syndrome, flurbiprofen axetil, FloTrac<sup>®</sup>, 696–701
- Meta-analysis
  - $\beta$ -blockers, remote ischemic preconditioning, cardiac surgery, 305–310
  - beta-blocking agents, on mortality, 834–843
  - isoflurane on survival and myocardial infarction, 50–56
  - milrinone on mortality, cardiac surgery, 220–227
  - mitral valve surgery, octogenarians, 213–218
  - myocardial protection, volatile anesthetics, cardiac surgery, 977–978
  - on- and off-pump CABG surgery, cognitive outcomes, 253–264
  - postoperative arrhythmias, CABG surgery, e49–e50
  - volatile anesthetics, remote ischemic preconditioning, cardiac surgery, 305–310
- Metabolic management, liver transplantation, 811–812
- Meta-regression, mitral valve surgery, octogenarians, 213–218
- Metastatic melanoma, right atrial mass, 821–823
- Methylene blue, 161–162, 164
  - systemic inflammatory response, 1000
  - for treatment of vasoplegia during cardiac surgery, 1233–1237
- Metoprolol vs. atenolol, day-of-surgery heart rate, 298–303
- Metrics evolution, in echocardiography, 1034–1039
- Midazolam, valvular heart surgery, 181
- Milrinone
  - inhaled therapy, pulmonary hypertension, 559
  - on mortality, cardiac surgery, 220–227
- Minimal vs. conventional extracorporeal circulation, coronary revascularization, 859–863
- Minimally invasive cardiac surgery, cardioplegia maldistribution, 614–618
- Minimally invasive repair, of pectus excavatum, 441–444
- Minocycline, ameliorating effects, neurologic disorders, e12–e13
- Mitochondrial permeability transition pore, sevoflurane, 916–923
- Mitral annulus, intraoperative echocardiographic perspective, 1355–1363
- Mitral inflow, during ventricular diastole, 96
- Mitral paravalvular leaks, percutaneous closure of, 168–176
- Mitral regurgitation
  - cause and effect, 1424
  - dyssynchrony, 1421–1424
  - ischemic, intraoperative echocardiography, 573–582
  - thoracic epidural anesthesia, cardiac surgery, 445–450
- Mitral valve disease, pulmonary veins, 116
- Mitral valve mass, transesophageal echocardiography, 1070–1072
- Mitral valve repair
  - internal jugular venous valves, 199–200
  - posterior and anterior leaflets, 95–97
- Mitral valve surgery, octogenarians
  - insights and perspectives, 201–202
  - pooled immediate and late outcomes, 213–218
- Morbidly obese patients, body surface area-indexed calculations, 1140–1144
- Morphine
  - intrathecal, 413–415
  - low-dose spinal, post-thoracotomy pain, 417–422
  - postoperative hyperactive-type delirium, cardiac surgery, 933–937
- Mortality
  - aortic valve replacement
    - hemoglobin level, 716–721
    - patient-prosthesis mismatch, 647–652
  - Mortality (*Continued*)
    - beta-blocking agents, 834–843
      - after cardiac surgery, 1194–1199
      - on milrinone, cardiac surgery, 220–227
      - following noncardiac surgery, 1277–1281
    - MostCare<sup>®</sup>, for cardiac output estimation, 1114–1120
    - Motor deficit index, 80
    - Moyamoya, cerebral oxygen saturation monitoring, 740–742
    - Multiple-pass hemoconcentration (MPH) method, for blood separation, 1174–1179
    - Muscles, supra- and infraspinatus, myofascial involvement, pain after thoracotomy and thoracic surgery, 1310–1314
    - Mustard procedure, acute ascending aortic dissection, 735–738
    - Mycobacterium tuberculosis, intraoperative transesophageal echocardiographic diagnosis of, e82–e84
    - Myocardial infarction
      - HIV, 141–142
      - meta-analysis of isoflurane, 50–56
  - Narcotrend EEG device, brain ischemia, e13–e14
  - Near-infrared spectroscopy
    - cardiac surgery
      - clinical utility, as standard monitor, 390–393
      - fluid challenges, 266–271
    - reflectance, for cerebral saturation measurement, 1260–1266
    - regional spectroscopy vs. 12-lead electroencephalogram, for ischemia detection, 1253–1258
  - Nefopam, early postoperative hyperalgesia, cardiac surgery, 427–434
  - Neonatal cardiac surgery, recombinant activated factor VIIa, e14–e15
  - Neurohumoral therapy, hypotension, 159–161
  - Neurologic disorders, ameliorating effects of minocycline, e12–e13
  - Neuromuscular blockade reversal agents, transplanted heart, 1374–1378
  - Neuron-specific enolase, cardiac surgery, 510–515
  - Nexfin
    - cardiac output measurement, e35–e37
    - pulse contour analysis, for cardiac output, 283–286
  - Nitroglycerin, pulmonary hypertension, 559
  - Noise, operating rooms, during surgery, 528–530
  - Noncardiac surgery
    - left ventricular assist devices, perioperative management, 752–758
    - levosimendan, 364
    - perioperative acute myocardial infarction, mortality, 1277–1281
    - preoperative cardiac risk assessment, 395–398
  - Nonimmune-mediated HIT, 341
  - Noninvasive cardiac output monitors, 121–130
  - Noninvasive cardiac stress testing, 396–397
  - Noninvasive ventilation
    - in cardiac surgery, e63–e64
    - helmet, transesophageal ecocardiography through, e78–e80
  - Nonpharmacologic management, systemic inflammatory response, 984, 990–992
  - Norepinephrine, 161, 163
    - infusion effect, on sublingual microcirculation, 1239–1244
  - Nuss procedure, perioperative anesthetic and surgical complications, 436–440
  - Obesity, body surface area-indexed calculations, 1140–1144
  - Obstetric hemorrhage, S44–S47
  - Occult pulmonary embolism, ICU patients, chest CT scan, 474–478
  - Octogenarians, mitral valve surgery
    - insights and perspectives, 201–202
    - pooled immediate and late outcomes, 213–218
  - Off-pump coronary artery bypass (OPCAB) graft surgery
    - cognitive outcomes, meta-analysis, 253–264
    - vs. on-pump coronary artery bypass grafting surgery, 5–11
    - oral triiodothyronine replacement therapy in, 1218–1223
    - quadriplegia after, e16–e17
    - revascularization, S-100 $\beta$  protein, 245–250
    - saphenous vein grafts for, 1208–1211
    - systemic inflammatory response, 992–993

- Off-pump transplant surgical procedure, 468
- Oliguria, in acute kidney injury after on-pump cardiac surgery, 1145–1152
- One-lung ventilation (OLV)
  - left-heart bypass, in pediatric patients, 542–545
  - prediction of volume-responsiveness during, 1094–1099
- On-pump coronary artery bypass grafting surgery
  - acute kidney injury after, 1145–1152
  - cognitive outcomes, meta-analysis, 253–264
  - vs. off-pump coronary artery bypass surgery, 5–11
- On-pump transplant surgical procedure, 468
- ON-Q local anesthetic-infiltrating catheter, 424–426
- OPCAB graft surgery. *See* Off-pump coronary artery bypass (OPCAB) graft surgery
- Operating rooms, noise levels, during surgery, 528–530
- Operative mortality, 214
- Outcome data, language and type of evidence, e7
- Outcomes
  - of cardiac surgery
    - oliguric criteria in acute kidney injury, 1145–1152
    - residual blood transfusion, 1174–1179
    - neurocognitive, cardiac surgery, 958–968
    - of pulmonary hypertension, 565–566
    - renin-angiotensin system inhibitors, cardiac surgery, 703–708
    - of transplantation, 566
    - ultrafiltration strategy, in pediatric cardiac surgery, 897–902
  - Out-of-hospital ventricular fibrillation survivors, therapeutic hypothermia, 288–290
- Oxidative stress, after carotid endarterectomy, 1246–1251
- Oximetry
  - cerebral, in cardiac surgery, 385–387
  - pulse, in extracorporeal membrane oxygenation, 340
- Oxygen metabolism, prostaglandin E<sub>1</sub> effects on, 1208–1211
- Pacemaker implantation, pneumothorax after, e73–e75
- Pacemakers, temporary external, accidental, unintentional reprogramming, 944–948
- Papillary fibroelastoma, right atrial, 822–823
- Paravalvular leaks
  - percutaneous closure, 168–176, e41–e43
  - transcatheter aortic valve replacement, 186
- Patent foramen ovale
  - pulmonary embolism, e30–e31
  - thrombus diagnosis, 195–196
- Patient-prosthesis mismatch, mortality, aortic valve replacement, 647–652
- Pediatric cardiac surgery
  - laryngoscopic view, 516–520
  - ultrafiltration strategy, clinical outcomes, 897–902
- Pediatric ultrasound-guided vascular access, 354
- Percutaneous closure
  - aortic valve, 1407–1413
  - atrial septal defect, 400–402
  - paravalvular leaks, e41–e43
- Percutaneous dilatational tracheostomy, low-frequency jet ventilation, 108–110
- Percutaneous mitral balloon valvotomy, 546–548
- Pericardial disease, HIV, 140–141
- Perioperative applications, of levosimendan, 361–365, e75–e77, e77–e78
- Perioperative coagulopathy, plasma vs. whole blood testing, S9–S13
- Perioperative conduction disturbances, after transcatheter aortic valve replacement, 1414–1420
- Perioperative evaluation, HIV+ patients, 143–146
- Perioperative immunomodulation, HIV+ patients, 146–147
- Perioperative management
  - ADP-receptor inhibitors, 779–789
  - extracorporeal membrane oxygenation, 335–337
  - left ventricular assist devices, noncardiac surgery, 752–758
- Perioperative practice search, 88–89
- Peripheral venous cannulation, 350, 354
- Permissive hypotension, S37–S38
- Pharmacologic management, systemic inflammatory response, 996–1002
- Phenylephrine, 159, 163
- Pheochromocytoma
  - perioperative management, 1399–1406
  - von Hippel-Lindau disease, clevidipine, 749–751
- Phosphodiesterase enzyme inhibitors, systemic inflammatory response, 1002
- Physiological compensatory response, artery exiting proximal aortic root, 410–412
- Plasma dilution, cardiopulmonary bypass with bleeding and morbidity, 845–850
- Plasma transfusion, goal-directed coagulation factor, S16–S18
- Plethysmographic variability index vs. pulse pressure variation, in fluid responsiveness prediction, 1087–1092
- Pleural puncture, ultrasound guided paravertebral block, e11–e12
- Pneumothorax, after pacemaker implantation, e73–e75
- POC tests. *See* Point-of-care (POC) tests
- Point-of care (POC) testing
  - fibrinogen levels measurement, 2
  - goal-directed hemostatic therapy, S24–S28
  - rotational thrombelastometry analysis, 5–11
  - vs. routine laboratory testing, S21
- Polypropylene membrane oxygenator performance, on sevoflurane, 903–907
- Posterior glenohumeral joint dislocation, CABG surgery, 101–102
- Posterior leaflet, repair and preservation of, 92–97
- Postoperative bleeding, in thoracic aortic surgery, 1201–1206
- Postoperative cognitive decline, 958–968
- Postoperative costs, antithrombin levels, extracorporeal circulation, 230–236
- Postoperative hyperactive-type delirium, morphine, cardiac surgery, 933–937
- Postoperative management
  - left ventricular assist devices, noncardiac surgery, 757–758
  - of pulmonary hypertension, 560–561
- Postoperative oxygenation, double-lung transplantation, 467–472
- Postpartum hemorrhage, S44–S47
- Postreperfusion syndrome, 809–810
- Post-thoracotomy pain
  - epidural vs ON-Q local anesthetic-infiltrating catheter, 423–426
  - low-dose spinal morphine, 417–422
- PRAM. *See* Pressure recording analytic method (PRAM)
- Prasugrel
  - cardiac tamponade, CABG surgery, e57–e58
  - pharmacokinetics, 780
  - P2Y<sub>12</sub> platelet blocker, 620–622
- Pregnancy
  - aortic dissection, cesarean delivery and repair, 731–733
  - hematologic and hemostatic alterations, S44
  - uncorrected, undiagnosed total anomalous pulmonary venous return, 1041–1046
- Preincisional transversus abdominis plane block, abdominal aortic aneurysm, 536–538
- Preoperative cardiac risk assessment, noncardiac surgery, 395–398
- Preoperative cognitive dysfunction, pulmonary complications after CABG surgery, 1267–1269
- Pressure recording analytic method, 124
  - for cardiac index assessment, 1108–1112
- Pressure waveform analysis, hemodynamic, 676–680
- Primary graft dysfunction, 469
- Primary pulmonary hypertension, HIV, 141
- Prognostic biomarker, hemoglobin A1c, 760–763
- Propofol
  - based vs. dexedetomidone-based sedation, cardiac surgery, 1289–1294
  - cardiac anesthetic agent, 178–179, 180–182
  - for carotid endarterectomy, 1246–1251
  - intravenous anesthetic agent, 146
  - neuron-specific enolase, cardiac surgery, 510–515
- Prostacyclins, pulmonary hypertension, 558–559

- Prostaglandin E<sub>1</sub>, in coronary artery bypass grafts, 1208–1211
- Prostate cancer, right atrial mass, 821–823
- Prosthetic aortic valve, three dimensional TEE, 1060–1063
- Protease inhibitor, systemic inflammatory response, 998
- Prothrombin complex concentrate, S27–S28
- Proximal aortic thrombus, 198
- Pulmonary artery catheter
  - cardiac index measurements after surgery with, 1108–1112
  - thermodilution cardiac output measurement, 1128–1138
- Pulmonary embolism
  - patent foramen ovale, e30–e31
  - subclavian intraport catheter, e10–e11
- Pulmonary gas embolism, hypoxia, cardiopulmonary bypass, 951–953
- Pulmonary hypertension
  - iloprost, cardiac surgery, 459–465
  - pathophysiology, perioperative management, outcomes, in cardiac surgery, 551–566
  - pregnancy, uncorrected, undiagnosed total anomalous pulmonary venous return, 1041–1046
  - tezosentan for, 1212–1216
- Pulmonary veins, intraoperative transesophageal echocardiography
  - left ventricular diastolic dysfunction, 115–116
  - left-sided, 113
  - and lung transplantation, 117
  - mitral valve disease, 116
  - right-sided, 112–113
  - stenosis, 117–118
  - thrombus, 118–119
- Pulmonary venous flow, 114
- Pulmonary venous obstruction, diagnosis, 119
- Pulsatile vs. nonpulsatile flow, systemic inflammatory response, 994
- Pulse contour analysis
  - comparative studies, 124
  - dynamic preload indices, 124–126
  - and lithium dilution, 123
  - noninvasive, cardiac output, 283–286
  - patient demographic and physical characteristics, 124
  - transpulmonary thermodilution, 123–124
- Pulse oximetry, extracorporeal membrane oxygenation, 340
- Pulse pressure variation
  - vs. digital plethysmographic variability index, fluid responsiveness prediction, 1087–1092
  - during infrarenal aortic cross-clamping, 1101–1106
- P2Y<sub>12</sub> platelet blockers, 620–622
- Quadriplegia, off-pump CABG surgery, e16–e17
- Quality improvement, after cardiac surgery, 1194–1199
- Recombinant activated factor VIIa, neonatal cardiac surgery, e14–e15
- Recurrent polymorphic ventricular tachycardia, 1067–1068
- Recurrent primary cardiac intimal spindle cell sarcoma, 103–106
- Refractory hypotension, 159–161
  - postoperative, Alfieri repair of mitral valve, e21–e22
- Regional anesthesia, vs. general anesthesia for carotid endarterectomy, 1379–1383
- Regional oxygen saturation, after acute kidney injury reconstruction, 1153–1157
- Renal complications, after coronary artery bypass grafting, 1167–1172
- Renal disease, end-stage, echogenic object in left atrium, 1429–1431
- Renin-angiotensin system inhibitors, cardiac surgery, 703–708
- Reoperative CABG surgery, sternal-sparing approach, 315–317
- Reperfusion injury, simvastatin, 79–83
- Respiratory mechanics, minimally invasive repair, of pectus excavatum and bar removal, 441–444
- Right atrial, echodensity, 1065–1066
- Right atrial papillary fibroelastoma, 822–823
- Right atrium, circular structure, 628–630
- Right ventricular dilatation, pulmonary thromboembolism
  - complicating acute type-a aortic dissection, 1432–1434
- Right ventricular dysfunction
  - combined bilateral lung-liver transplantation, 1343–1346
  - iloprost, cardiac surgery, 459–465
- Right ventricular failure, tezosentan for, 1212–1216
- Right ventricular outflow tract sarcoma, intraoperative TEE, e54–e55
- Right ventricular volume assessment, three-dimensional, 367–374
- Right-sided pulmonary veins, 112–113
- Risk models, cardiac risk stratification, 397–398
- Robotic surgery
  - CABG surgery, 802–804, e81
  - coronary revascularization, 806–808, e81
  - increases morbidity and mortality, e81
- Robotically assisted TECAB surgery, 586–597
- Rotational thrombelastometry (ROTEM), 5–11
- R-wave gated acquisition mode, 379
- Saphenous vein grafts flow, prostaglandin E<sub>1</sub> effect, 1208–1211
- S-100β protein
  - neuron-specific enolase, cardiac surgery, 510–515
  - off-pump CABG surgery revascularization, 245–250
- Sedation
  - in cardiac surgery, propofol-based vs. dexmedetomidine-based, 1289–1294
  - transfemoral aortic valve replacement, 46–48
- Sevoflurane
  - anesthesia during hypothermic cardiopulmonary bypass, 59–61
  - for carotid endarterectomy, 1246–1251
  - effects of catecholamines on microcirculation during inhalation of, 1239–1244
  - ethanol preconditioning, phosphorylation of glycogen synthase kinase-3β, 916–923
  - polypropylene membrane oxygenator performance, 903–907
- Simulation
  - in echocardiography, 1034–1039
  - online, on learning, transesophageal echocardiography, 531–534
  - TEE, senior anesthesiology residents, 670–674
- Single-beat acquisition mode, 378–379
- Sonography, diagnostic value of, e73–e75
- Soluble endothelial protein C receptor, 38
- Spinal cord ischemia-reperfusion injury, simvastatin, 79–83
- Statins
  - protective effects, 81–82
  - systemic inflammatory response, 998, 1000
- Statistical analysis
  - low-dose spinal morphine, post-thoracotomy pain, 417–422
  - milrinone on mortality, cardiac surgery, 221
  - mitral valve surgery, octogenarians, 214–215
  - plasma dilution, cardiopulmonary bypass with bleeding and morbidity, 846
- Stenosis
  - aortic, 190–192
  - aortic, vortex formation time, aortic valve replacement, 660–663
  - pulmonary veins, 117–118
- Sternal-sparing approach, reoperative CABG surgery, 315–317
- Sterotomy, anterior tracheal injury, e60–e61
- Steroids, in cardiac surgery, 1053–1058
- Stress testing, 146
- Stroke
  - transcatheter aortic valve replacement, 185–186
  - volume, in morbidly obese patients, 1140–1144
  - in women and aorta, 197–198
- Stroke volume index, goal-directed therapy using, e1075–e1078
- Subclavian intraport catheter, spontaneous rupture, e10–e11
- Subclavian vein cannulation, 349
- Sublingual microcirculation, during sevoflurane inhalation, catecholamines infusions effects, 1239–1244
- Sufentanil, target effect-site concentrations, 63–69
- Surgical and critically ill patients, hemoglobin A1c, 760–763
- Survival effects, meta-analysis of isoflurane, 50–56
- Symptomatic left ventricular diverticulum, case study, 949–950
- Systemic inflammatory response, inflammatory mediators, 983–1006

- Target effect-site concentrations, sufentanil, 63–69
- TEE. *See* Transesophageal echocardiography (TEE)
- Temporary external pacemakers, accidental, unintentional reprogramming, cardiac arrest, 944–948
- Terlipressin, 160, 163–164
- Tetralogy of Fallot (TOF)
  - ε-aminocaproic acid, 23–28
  - perioperative management, 1399–1406
  - repair, left atrial contrast opacification, 631–633
- Tezosentan Administration before Cardiopulmonary Bypass to Improve Cardiopulmonary Separation from Bypass (TACTICS) trial, 1212–1216
- Therapeutic hypothermia
  - on nonpulsatile continuous-flow after brain death, e8, e9–e10
  - out-of-hospital ventricular fibrillation survivors, 288–290
- Thermodilution
  - cardiac index measurements after surgery with, 1108–1112
  - cardiac output measurement, 1128–1132, 1133–1138
- Thiopental, coronary artery disease, 181
- Thoracic anesthetic practice, Italy, 1321–1330
- Thoracic aorta, ascending, 1425–1428
- Thoracic aortic surgery
  - tranexamic acid vs. epsilon aminocaproic acid, 1201–1206
  - vocal cord paralysis, 522–526
- Thoracic bioimpedance, 126
- Thoracic epidural analgesia, cardiac surgery
  - dismissal in, e32
  - outcome in low-to-moderate risk patients, 1301–1309
  - performance, e34–e35
- Thoracic epidural anesthesia, mitral regurgitation, cardiac surgery, 445–450
- Thoracic osteophyte, in cardiac surgery, for TEE, 319–320
- Thoracic paravertebral space, computerized tomographic anatomic relationships, 1315–1320
- Thoracoabdominal aortic surgery. *See* Spinal cord ischemia-reperfusion injury, simvastatin
- Thoracolumbar spinal decompression, left ventricular wall rupture, 98–99
- Three-dimensional echocardiography
  - aortic valve, 376–380
  - atrial septal defect, percutaneous closure of, 400–402
- Three-dimensional right ventricular volume assessment, 367–374
- Three-dimensional transesophageal echocardiography, 190–192
  - coronary ostium, transapical aortic valve implantation, 654–658, e53–e54
  - percutaneous mitral balloon valvotomy, 546–548
  - prosthetic aortic valve, 1060–1063
  - right heart, 637–638
  - tricuspid annular geometry, 639–645
- Thrombin, cardiopulmonary bypass, 35–39
- Thrombocytopenia, heparin-induced, 30–33
- Thromboelastometry, S21–S22
- Thromboelastometry-guided coagulation management, 1181–1187
- Thromboembolism, massive pulmonary, right ventricular dilatation, 1432–1434
- Thrombosis
  - left ventricular, peripheral venoarterial extracorporeal life support, e48–e49
  - postoperative hepatic artery, lung-liver transplantation, 1343–1346
- Thrombotic endotracheal tube occlusion, recombinant factor VIIa, 1330–1333
- Thrombus
  - patent foramen ovale, 195–196
  - proximal aortic, 198
  - pulmonary veins, 118–119
- Ticagrelor
  - bleeding, type A aortic dissection, e55–e57
  - pharmacokinetics, 780–781
  - P2Y<sub>12</sub> platelet blocker, 621
- Ticlopidine, pharmacokinetics, 779–789
- TOF. *See* Tetralogy of Fallot
- Topical and intravenous tranexamic acid, CABG surgery, 18–21
- Total intravenous anesthesia, fospropofol, safety and efficacy studies, CABG surgery, 908–914
- Totally endoscopic coronary artery bypass (TECAB) surgery, robotically assisted, 586–597
- Tracheal extubation, in sufentanil, after valve surgery, 63–69
- Tracheoesophageal fistula repair, thoracoscopic, end-tidal carbon dioxide, 539–541
- Tranexamic acid, for blood conservation, 1201–1206
- Transapical aortic valve implantation, coronary ostium, 654–658, e53–e54
- Transcatheter aortic valve implantation, endovascular, 765–776
- Transcatheter aortic valve replacement
  - anesthesia for, 46–48
  - perioperative conduction disturbances after, 1414–1420
  - vascular complications, stroke and paravalvular leaks, 184–187
- Transcutaneous cerebral oximetry, extracorporeal membrane oxygenation, 340
- Transesophageal echocardiography (TEE)
  - and anesthesiologists, 627
  - cardioplegia maldistribution, minimally invasive cardiac surgery, 614–618
  - cervical and thoracic osteophytes, cardiac surgery, 319–320
  - diagnosis and management of paradoxical carbon embolism, e23–e24
  - during aortic valve bypass surgery, e22–e23
  - during laparoscopic surgery, with hemodynamic compromise, e23–e24
  - episodic monoplane, cardiac surgery, 665–668
  - foreign body removal, from heart, 321–322
  - immobile probe, cardiopulmonary bypass, 955–957
  - intraoperative, 111–119
    - iatrogenic type-A aortic dissection, 326–327
    - right ventricular outflow tract sarcoma, e54–e55
  - through non-invasive ventilation helmet, e78–e80
  - online simulation, on learning, 531–534
  - precardiopulmonary bypass, 93–95, 190
  - preoperative, mitral valve mass, 1070–1072
  - simulation, senior anesthesiology residents, 670–674
  - severe aortic stenosis, e82
  - totally endoscopic coronary artery bypass surgery, 594–595
  - transcatheter aortic valve implantation, 774–775
- Transfusion
  - adult patients undergoing liver transplantation, 41–44
  - allogeneic blood products, 1181–1187
  - goal-directed therapy, S6–S7
  - plasma exchange, for altered heparin responsiveness, e58–e60
  - plasma, goal-directed coagulation factor, S16–S18
  - practices, in cardiac surgery patients, 1189–1193
  - systemic inflammatory response, 995
  - using centrifugation and multiple-pass hemoconcentration, 1174–1179
- Transient ischemic attack, 13
- Transplant surgical procedure, 469
- Transplantation
  - cardiac
    - HIV patients, 148–149
    - unusual findings, 404–405
  - double-lung, cardiopulmonary bypass, 467–472
  - heart-lung, pulmonary hypertension, 565
  - liver
    - anesthesia for, 812–813
    - cardiovascular risk, 812
    - metabolic management, 811–812
    - transfusion changes, 41–44
    - vasoplegia, 810
  - lung
    - pulmonary hypertension, 565
    - pulmonary veins and, 117
- Transpulmonary thermodilution, pulse contour analysis, 123–124

- Trauma, in hemorrhage, S35–S40  
Tribute, to Kolff, W.J., 600–613  
Tricuspid annular geometry, Three dimensional TEE, 639–645  
Triiodothyronine replacement therapy, in off-pump coronary artery bypass graft surgery, 1218–1223  
Troponin, cardiac risk stratification, 397  
Type-A aortic dissection  
  carotid flow, transcutaneous ultrasound, 728–730  
  ticagrelor-associated bleeding, e55–e57  
  ulinastatin, deep hypothermic circulatory arrest, 479–483  
Ulinastatin, type-A aortic dissection, deep hypothermic circulatory arrest, 479–483  
Ultrafiltration  
  strategy, in pediatric cardiac surgery, 897–902  
  systemic inflammatory response, 995  
Ultrasound  
  destruction, air emboli, cardiac surgery, 876–882  
  transcutaneous, carotid flow, type-A aortic dissection, 728–730  
Ultrasound guided paravertebral block, e11–e12  
Ultrasound-guided vascular access, 345–357  
Unfractionated heparin, 30  
Valsalva aneurysm, noncoronary sinus of, 629–630  
Valve surgery, sufentanil effect-site concentrations after, 63–69  
Valvular heart surgery, midazolam, 181  
Vascular complications, transcatheter aortic valve replacement, 184–185  
Vascular surgery, cardiac risk stratification, 397–398  
Vasoactive-inotropic score, levosimendan and, e15–e16  
Vasoplegia  
  during cardiac surgery, use of methylene as treatment for, 1233–1237  
  liver transplantation, 810  
Venoarterial extracorporeal membrane oxygenation, 329–342  
Venous drainage, impaired, atrial septal aneurysm in cardiac surgery, 1339–1342  
Venovenous extracorporeal membrane oxygenation, 329–342  
  esmolol, e40  
  internal jugular dual-lumen, e46–e47  
Ventricular assist-devices  
  gastrointestinal bleeding, hormonal therapy, 939–942  
  HIV patients, 148  
Ventricular septal defect, delayed postmyectomy, 381–384  
Ventricular tachycardia, recurrent polymorphic, 1067–1068  
Vigileo system, pulse contour analysis, 124–125  
Vocal cord paralysis, aortic surgery, 522–526  
Volatile anesthetics  
  cardioprotection, remote ischemic preconditioning, 305–310  
  myocardial protection, cardiac surgery, 972–979  
von Hippel-Lindau disease, pheochromocytoma, clevidipine, 749–751  
Vulvular surgery, HIV patients, 148  
Weaning, extracorporeal membrane oxygenation, 340  
Whole-blood impedance aggregometry, S22–S24